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Dr David H. Adams (New York, NY). By way of disclosure, I
am an inventor with a royalty agreement with Edwards.
John, I would like to congratulate you on a job well done with
your presentation and manuscript. We all admire the enormous
contributions from the Mayo Clinic to our understanding of the
timing for intervention in mitral valve disease, most recently sum-
marized in an excellent review published earlier this year in Circu-
lation by Maurice Sarano and our Secretary, Thor Sundt.
Essentially, all the class I triggers for intervention in the guide-
lines, including LV end-systolic dimension, ejection fraction, and
the development of symptoms, result from clinical research from
the Mayo Clinic.
In this article you attempt to add significant LVH to the list of
potential indications for valve repair in patients with prolapse. Al-
though I agree with the benefit of operating on patients with severe
regurgitation early in the course of their disease to protect the ven-128 The Journal of Thoracic and Cardiovascular Surgtricle, I am not convinced yet that your study has provided suffi-
cient data to elevate LVH or the likelihood of ventricular
remodeling to our list of triggers. I have a few questions.
You mentioned early surgical intervention in the title of your ar-
ticle, which is never really defined. I know your institution has
been a leading proponent of early surgical intervention in asymp-
tomatic patients with preserved LV function, and therefore I would
like to understand your data in this context. Your landmark article
first authored by Seano on this topic was published in 2005, yet
surely many patients in this study were operated on in an early set-
ting because that particular article took a few years to actually
come out in print. The LVEF was 65% or greater in all 3 terciles,
and you did you not see a difference in functional class between
cohorts. Therefore there seems no clear indication that higher
LVMI in selected patients reflected delayed surgical intervention.
Can you tell us what exactly you define as early surgical interven-
tion and also the proportion of patients in each tercile defined by
LVMI who had early surgical intervention as you define it?
Dr Stulak. Thank you, Dr Adams. We appreciate you being our
discussant. At Mayo Clinic, we operate on patients who are well
within class I and class IIA indications; however, prior studies
from our institution have demonstrated superior outcomes when
operations are undertaken when the LVEF is between 60% and
65% and when the LV end-systolic dimension is between 36 and
40 mm. That is what we define as the criteria for early mitral valve
repair.
Dr Adams. Can you tell us why LVMI was not quantifiable in
approximately 15% of your cohort? You excluded about 15% of
patients, saying you could not calculate LVMI. Can you tell us
why that was and what your protocol was for defining it?
Dr Stulak. This study period was from 1995 to 2005. Standard-
ization of the reporting of echocardiographic data did not become
common practice until the late 1990s. Therefore the most com-
monly missed measurement was posterior wall thickness. For
the calculation of LVMI, we used the equation set forth by the
American Society of Echocardiography. I would surmise that
those 15% of patients probably were lost during that lack of stan-
dardization time period.
Dr Adams. John, in another article from your institution this
year, a preoperative LV end-systolic dimension of greater than
40 mm was identified as a predictor of late mortality after mitral
valve repair. Why do you think a high LVMI was not associated
with late mortality? Do you think hypertension in more than a third
of your patients is the confounder that really explains this?
Dr Stulak. We were surprised at the finding that there is no dif-
ference in late survival, and I believe that there are several reasons
to explain this finding. First, hypertension could have been a con-
founder; however, this was not found to be independently associ-
ated with a multivariable model. Furthermore, patients with and
without hypertension had a similar degree of LV mass regression.
Second, this is a retrospective study using historical echocardio-
graphic data and obvious limitations exist. Third, it is a highly se-
lected patient population with a single cause of MR. This lack of
difference in survival actually is what has been observed in studies
examining patients with aortic stenosis who have had incomplete
mass regression. Therefore I think that prospective collection of
data in a larger patient population is warranted beforewe can really
draw firm conclusions.ery c January 2011
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DDrAdams. And, of course, we need to know better how that hy-
pertension gets managed.
Dr Stulak. Absolutely.
Dr Adams. My last question is this: Given the detrimental ef-
fect of LVH on LV function, do you think we should incorporate
LVMI in our future decision-making algorithms and guidelines?
Specifically, in a patient with normal ventricular function, an ejec-
tion fraction of 70%, normal dimension, LV systolic dimension of
34 mm, and severe MR, would you regard a low or normal LVMI
as an indication that watchful waiting rather than surgical interven-
tion would be an appropriate strategy? In other words, are you go-
ing to counsel patients? I understand that if they have a high LVMI,
you are going to say that they should have an operation, but would
a completely normal LVMI maybe sway you toward watchful
waiting?
Dr Stulak. Another great question. I do not think that LV mass
rises to the same bar as ejection fraction and LV end-systolic di-
mension. Prior studies from our institution have documented ex-
cellent outcomes if the ejection fraction is normal and the LV
end-systolic dimension is normal. I do not believe this study is de-
signed to answer that question, but I do not think that a low LVMI
would affect our decision to undertake surgical intervention in
patients presenting early.
Dr Adams. John, congratulations.
DrA.W.Atkinson (Raleigh, NC). I just want to touch on a point
that Dr Adams made, and I think it was in your discussion about
the confounding of hypertension. In particular, do you have any
data on the postoperative management with afterload reduction
until a return of normal LVMI?
Dr Stulak. That is an outstanding question, and this is certainly
one of the limitations of this study. Although some patients are fol-
lowed very aggressively at Mayo Clinic by the cardiologists, we do
lose certain patients from distances to the community and their
personal primary care physicians. Those followed at Mayo ClinicThe Journal of Thoracic and Caare treated with an aggressive regimen of b-blockade and angio-
tensin-converting enzyme inhibition. I think to overcome this lim-
itation, prospectively collected data and more accurate follow-up
of hypertension control are crucial.
Dr Rakesh M. Suri (Rochester, Minn). John has done a fan-
tastic job on this study. I just wanted to comment on Dr Adams’
question. Of course, this is a very unique cohort of patients who
all underwent early mitral valve surgery well within class I or
class IIa guidelines, and as such, the findings are not surprising.
They all have good late survival and a low incidence of late
complications or stroke. The study was designed to characterize
the change in LV mass following mitral valve repair and to un-
derstand factors influencing regression of ventricular hypertro-
phy. The separate question as to whether we can safely wait
to allow LVH to develop cannot be addressed within the current
study. Previous series have clearly demonstrated, however, that
‘‘watchful waiting’’ of patients severe MR once guideline-based
surgical indications have been met, is associated with dire clin-
ical consequences.
DrHarold L. Lazar (Boston, Mass). I just want to follow up on
the questions that Dr Adams raised about the pathophysiology for
the mass regression. Did you look at the patients you actually ex-
cluded from the study, those with atrial fibrillation and coronary
artery disease, to see whether there was a similar change in mass
regression? In other words, does the presence of atrial fibrillation
or coronary artery disease inhibit mass regression in patients who
have valve repair for posterior leaflets?
Dr Stulak. That is an outstanding point, and we are currently
actually looking at each different subset of those 2600 mitral valve
repairs from all causes. Again, we wanted to start our investigation
with a homogenous population, taking every possible confounding
effect of cause out of the equation. Then, on interpreting our re-
sults, we were very enticed. Therefore we are going to extend
this to larger groups of patients. You make a great point.rdiovascular Surgery c Volume 141, Number 1 129
